Elevation Wealth Partners’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$86.9K Sell
1,392
-25
-2% -$1.58K 0.02% 228
2026
Q2
$81.6K Buy
1,417
+260
+22% +$14.9K 0.02% 212
2026
Q1
$70.2K Buy
1,157
+40
+4% +$2.33K 0.03% 198
2025
Q4
$60.3K Buy
1,117
+344
+45% +$16.5K 0.02% 213
2025
Q3
$34.9K Buy
773
+94
+14% +$4.39K 0.01% 278
2025
Q2
$31.4K Hold
679
– – 0.01% 282
2025
Q1
$41.4K Hold
679
– – 0.02% 253
2024
Q4
$38.4K Hold
679
– – 0.02% 254
2024
Q3
$35.1K Hold
679
– – 0.02% 256
2024
Q2
$28.2K Hold
679
– – 0.01% 264
2024
Q1
$36.8K Hold
679
– – 0.02% 245
2023
Q4
$39.4K Hold
679
– – 0.02% 224
2023
Q3
$39.4K Hold
679
– – 0.03% 165
2023
Q2
$43.4K Hold
679
– – 0.04% 170
2023
Q1
$47.1K Buy
+679
New +$47.9K 0.04% 162

Other funds holding BMY

Elevation Wealth Partners's BMY Position: Q3 2026 in Review

Elevation Wealth Partners reduced its Bristol-Myers Squibb (BMY) stake by 1.8% in Q3 2026, selling an estimated $1.58K and leaving 1,392 shares worth $86.9K. The position accounts for 0.02% of the portfolio, ranked #228.

Elevation Wealth Partners first reported a position in BMY in Q1 2023 and has held it in 15 quarters since. 1,520 funds tracked by Wall St. Rank hold BMY as of Q3 2026.

  • Elevation Wealth Partners held 1,392 shares of Bristol-Myers Squibb worth $86.9K as of Q3 2026.
  • Elevation Wealth Partners sold 25 Bristol-Myers Squibb shares in Q3 2026, an estimated $1.58K.
  • Bristol-Myers Squibb made up 0.02% of Elevation Wealth Partners's portfolio in Q3 2026, its #228 holding.
  • Elevation Wealth Partners first reported a position in Bristol-Myers Squibb in Q1 2023 and has held it in 15 quarters since.
  • 1,520 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2026.

Based on Elevation Wealth Partners's 13F filing for Q3 2026, filed 7 Oct 2026.